OncorMed, ONYX Pharmaceuticals deal

ONM will conduct p53 testing for Phase I trials of ONXX's ONYX-015. The compound is a genetically engineered adenovirus designed to selectively kill tumor cells deficient in p53 tumor suppressor activ...